Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis

NCT01863888 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: teriflunomide HMR1726
DRUG: cholestyramine
DRUG: charcoal

Sponsor

Sanofi